AxoGen (AXGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 8. On the o ...

ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may d ...

AxoGen (AXGN) shares ended the last trading session 8.2% higher at $8.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks.Axogen scored a strong price increase, driven by the optimism surrounding the launch of its latest nerve protection solution, Avive+ Soft Tissue Matrix, last month. Besides, the company is expected to release its second-quarter 2024 results in August. In the fi ...

ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee. In connection with the commencement of employment on June 17, 2024, and as a material inducement of employment, an award was made under the Company’s Inducement ...

AxoGen (AXGN) recently announced the full launch of its latest product, Avive+ Soft Tissue Matrix. Avive+ is a resorbable, multi-layer amniotic membrane allograft designed for use as a soft tissue barrier. It offers temporary tissue separation and protection during the crucial stage of peripheral nerve recovery.With the introduction of Avive+ Soft Tissue Matrix, Axogen is likely to enhance its comprehensive solutions for nerve protection and address a significant need for patients with compression or non-tr ...

ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is proces ...

ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is proce ...

Company Overview - AxoGen (AXGN) shares increased by 5.4% to $7.38 in the last trading session, with a notable trading volume, and have gained 20.9% over the past four weeks [1] - The company announced the opening of the Axogen Processing Center (APC) in Vandalia, Ohio, scheduled for June 12, 2024, which will process its Avance Nerve Graft, indicating potential for significant future growth [1] Financial Expectations - AxoGen is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of -100%, while revenues are projected to be $43.35 million, an increase of 13.6% from the previous year [1] - The consensus EPS estimate for AxoGen has remained unchanged over the last 30 days, suggesting that stock price movements may not sustain without trends in earnings estimate revisions [2] Industry Context - AxoGen is part of the Zacks Medical - Instruments industry, where another company, Artivion (AORT), saw a 0.6% increase in its stock price to $23.40, with a return of 0.3% over the past month [2] - Artivion's consensus EPS estimate for the upcoming report is unchanged at $0.03, representing a -50% change from the previous year, and it also holds a Zacks Rank of 3 (Hold) [3]

ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will celebrate the opening of its Axogen Processing Center (APC) with leaders of the Ohio community on June 12, 2024. APC is designed to process Avance Nerve Graft®, a regenerative peripheral nerve scaffold indicated for the treatment of peripheral nerve functional deficit and used by surg ...

ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will celebrate the opening of its Axogen Processing Center (APC) with leaders of the Ohio community on June 12, 2024. APC is designed to process Avance Nerve Graft®, a regenerative peripheral nerve scaffold indicated for the treatment of peripheral nerve functional deficit and used by surge ...